Improved survival of Eμ-TEL/PDGFβR transgenic mice treated with the specific tyrosine kinase inhibitor CGP57148. (A) Premalignant mice model: 6 I-line mice between 5 and 7 weeks old without evidence of malignancy on examination were treated with daily IP injections of CGP57148 for 30 days (—). Concurrently, 9 similar animals were treated with PBS as a control (——). Time to development of overt malignancy is delayed and survival is improved in animals treated with CGP57148. (B) Tumor transplant model: tumor cells from an I-line mouse with massive lymphadenopathy were put into single-cell suspension, and 104 cells were injected into sublethally irradiated syngeneic mice. Ten were treated with CGP57148 (—) and 9 were treated with PBS (—-) for 21 days. Again, mice treated with CGP57148 had a statistically significant improvement in survival. In both figures, an open bar represents the duration and timing of CGP57148 or PBS.
